3 results
Approved WMORecruiting
Primary objective:• To evaluate the anticancer efficacy of INBRX-109 in the intention-to-treat (ITT) population as measured by progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECISTv1.1), assessed by…
Approved WMORecruiting
PART I:Primary:• To investigate the safety and tolerability of two doses of VAD044 administered daily for up to 12 weeks in HHT patients.Secondary:• To assess the effects of two doses of VAD044 for up to 12 weeks of treatment on:o Epistaxis:•…
Approved WMOPending
To assess the efficacy of inhaled RVT-1601 in comparison with placebo following 12 weeks of treatment